NLRC4-MAS

Clinical trial pipeline · Data from ClinicalTrials.gov

See which NLRC4-MAS trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingNot Applicable

NCT02974595

Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Stil…

Background: Some diseases cause chronic inflammation with intermittent flares in the body. These are called autoinflammatory diseases. They can cause fevers, r…

United States3,200 participantsStarted 2016-12-09

All recent trials (4 shown)

Active — Not RecruitingPhase 2

NCT04641442

Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammato…

This study is a Phase 2 trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 in patients with NLRC4-GOF, XIAP deficiency, or CDC…

United States17 participantsStarted 2020-12-18

Treatment: MAS825, Placebo

CompletedPhase 3

NCT03113760

Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency

This is a Phase 3 study to assess the safety and efficacy of Tadekinig alfa in patients with monogenic, interleukin-18 (IL 18) driven autoinflammation due to Nu…

United States15 participantsStarted 2017-07-21

Treatment: Tadekinig alfa, 0.9% sodium chloride

NLRC4-MAS

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Stil…

All recent trials (4 shown)

Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammato…

Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Stil…

All recent trials (4 shown)

Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammato…

Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency

Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency As Open Label Extension